

# p73 Plays a Role in Erythroid Differentiation through GATA1 Induction<sup>\*[S]</sup>

Received for publication, January 5, 2009, and in revised form, May 28, 2009. Published, JBC Papers in Press, June 9, 2009, DOI 10.1074/jbc.M109.026849

Fernando Marqués-García<sup>†1</sup>, Nuria Ferrandiz<sup>§2</sup>, Rosalía Fernández-Alonso<sup>‡2</sup>, Laura González-Cano<sup>‡3</sup>, Marta Herreros-Villanueva<sup>‡2</sup>, Manuel Rosa-Garrido<sup>§4</sup>, Belén Fernández-García<sup>‡3</sup>, José P. Vaque<sup>§2</sup>, Margarita M. Marqués<sup>¶</sup>, María Eugenia Alonso<sup>||</sup>, José Carlos Segovia<sup>||</sup>, Javier León<sup>§</sup>, and María C. Marín<sup>‡5</sup>

From the <sup>‡</sup>Instituto de Biomedicina and the <sup>¶</sup>Instituto de Desarrollo Ganadero y Sanidad Animal, Universidad de León, 24071 León, the <sup>||</sup>Grupo de Biología Molecular del Cáncer, Departamento de Biología Molecular, Unidad de Biomedicina del Consejo Superior de Investigaciones Científicas, Haematopoiesis Division, CIEMAT-CIBERER Instituto Salud Carlos III, 28040 Madrid, and the <sup>§</sup>Instituto de Biomedicina y Biotecnología de Cantabria, Universidad de Cantabria, Consejo Superior de Investigaciones Científicas, 39011 Santander, Spain

The *TP73* gene gives rise to transactivation domain-p73 isoforms (TAp73) as well as  $\Delta$ Np73 variants with a truncated N terminus. Although TAp73 $\alpha$  and  $\beta$  proteins are capable of inducing cell cycle arrest, apoptosis, and differentiation,  $\Delta$ Np73 acts in many cell types as a dominant-negative repressor of p53 and TAp73. It has been proposed that p73 is involved in myeloid differentiation, and its altered expression is involved in leukemic degeneration. However, there is little evidence as to which p73 variants (TA or  $\Delta$ N) are expressed during differentiation and whether specific p73 isoforms have the capacity to induce, or hinder, this differentiation in leukemia cells. In this study we identify *GATA1* as a direct transcriptional target of TAp73 $\alpha$ . Furthermore, TAp73 $\alpha$  induces *GATA1* activity, and it is required for erythroid differentiation. Additionally, we describe a functional cooperation between TAp73 and  $\Delta$ Np73 in the context of erythroid differentiation in human myeloid cells, K562 and UT-7. Moreover, the impaired expression of *GATA1* and other erythroid genes in the liver of p73KO embryos, together with the moderated anemia observed in p73KO young mice, suggests a physiological role for *TP73* in erythropoiesis.

The *TP73* gene gives rise to multiple protein isoforms because of alternative mRNA splicing and promoter utilization as follows: TAp73 isoforms (containing the N-terminal transactivation domain) and TA-deficient  $\Delta$ Np73 isoforms (1–5). The *TP73* gene expresses at least seven C-terminal isoforms ( $\alpha$ ,  $\beta$ ,  $\gamma$ ,  $\delta$ ,  $\epsilon$ ,  $\zeta$ , and  $\eta$ ) that differ in their transcriptional activity and at least four alternatively spliced  $\Delta$ N isoforms initiated at dif-

ferent ATG (6, 7). TAp73 $\alpha$  and  $\beta$  share many target genes with p53, inducing cell cycle arrest, apoptosis, and differentiation (8–11). Conversely,  $\Delta$ Np73 isoforms can act as a dominant-negative suppressor of p53 and TAp73, abrogating their proapoptotic, differentiation, and growth suppression functions in diverse cell types (5, 12, 13). Nevertheless, several lines of evidence have revealed that  $\Delta$ Np73 can also transactivate specific target genes, including neuronal pro-differentiation genes such as *BTG2*, and may either inhibit or stimulate p53 transcriptional activity, depending on the gene and the cellular context (14–18). These findings imply that  $\Delta$ Np73 $\alpha$  not only acts as an inhibitor of p53/TAp73 but can also cooperate with them. Furthermore, the recent observations that  $\Delta$ Np73 acts as a pro-differentiation factor in acute promyelocytic leukemia cells and might be necessary for myeloid differentiation suggest that the functional role of  $\Delta$ Np73 in the context of myeloid differentiation may differ from that in other cell types (19). However, the existence of a functional cooperation between  $\Delta$ Np73 $\alpha$  and TAp73 in myeloid cell differentiation remains unclear.

A model to explain p73 function in myeloid differentiation and leukemogenesis has been proposed based on the analysis of the p73 status in patients with advanced stages of chronic myeloid leukemia and acute myeloid leukemia. In this model, inappropriate expression of certain p73 isoforms could result in impaired cellular differentiation giving rise to leukemic cells (20, 21). However, there is little evidence as to which p73 variants (TA or  $\Delta$ N) are expressed during differentiation and whether specific p73 isoforms have the capacity to induce, or hinder, this differentiation in leukemia cells.

In the process of addressing these questions, we found that constitutive expression of  $\Delta$ Np73 in the human cell lines, K562 and UT-7, resulted in erythroid differentiation. Further analysis revealed that  $\Delta$ Np73-induced erythroid differentiation required transcriptionally active TAp73. We demonstrated that TAp73 is capable of inducing *GATA1* activity and is required for drug-induced *GATA1* expression and differentiation. Consistent with an *in vivo* role for p73 in red blood cell differentiation, p73-deficient mice presented with moderate anemia as well as impaired expression of *Gata1* and other erythroid related genes. Altogether, our data demonstrate a role of *TP73* in erythroid differentiation and suggest a physiological role of this gene in developmental erythropoiesis.

\* This work was supported by Grants SAF2006-10756, SAF2005-00461, SAF2008-1883, and RETIC-RD06/0020 from Spanish Ministerio de Educación y Ciencia (to M. C. M., J. L. S., and J. C. S.) and Grant LE030A07 from the Junta de Castilla y León (to M. M. M.).

[S] The on-line version of this article (available at <http://www.jbc.org>) contains supplemental Figs. 1–5 and Table 1.

<sup>1</sup> Recipient of a fellowship from the University of León, León, Spain.

<sup>2</sup> Recipient of predoctoral fellowship from the Spanish Ministerio de Educación y Ciencia.

<sup>3</sup> Recipient of predoctoral fellowships from Consejería de Educación y Cultura de la Junta de Castilla y León and Fondo Social Europeo.

<sup>4</sup> Recipient of a University of Cantabria fellowship.

<sup>5</sup> To whom correspondence should be addressed: Instituto de Biomedicina, Universidad de León, Campus de Vegazana, 24071 León, Spain. Tel.: 34-987-291793; E-mail: carmen.marin@unileon.es.

## Role of TP73 in Erythroid Differentiation

### EXPERIMENTAL PROCEDURES

**Mice Husbandry and Dissection of Hematopoietic Tissue**—Animal experimental procedures were conducted in agreement with European (Council Directive 86/609/CEE) and Spanish regulations (RD 1201/2005) for the protection of animals used for experimental and other scientific purposes. Mice heterozygous for TP73 on a mixed background C57BL/6 × 129/svJae were backcrossed, at least five times, to C57BL/6 to enrich for C57BL/6. Mice were genotyped as described before (4). Pregnant females at 14.5 days postcoitum (E14.5) were euthanized, and embryos were extracted and visually inspected independently by two different investigators. Fetal livers were dissected and processed to obtain RNA as described below.

**Cell Culture**—K562, HCT-116 p53<sup>-/-</sup>, and UT-7 cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum. UT-7 medium was supplemented with granulocyte-macrophage colony-stimulating factor 5 ng/ml.

**Plasmids and Transfection**—The cDNAs from human HA-TAp73 $\alpha$ , TAp73 $\alpha$ 292, HA- $\Delta$ Np73 $\alpha$ , and pcDNA3-HA-TAp73 $\epsilon$  were described previously (22). The reporter plasmid GATA1-Luc (a gift from Dr. T. Nakano, Osaka University) contains a fragment of the *GATA1* promoter, including three GATA1-binding sites (23). The cDNA from human HA- $\Delta$ Np73 $\alpha$  was subcloned in the plasmid MT-CB6<sup>+</sup> (a gift from Dr. Frank J Rauscher) in the KpnI/XbaI sites.

To generate K562-HA- $\Delta$ Np73 $\alpha$ , - $\Delta$ Np73 $\beta$ , and -HA-TAp73 $\epsilon$  cell lines, K562 cells ( $2 \times 10^6$ ) were electroporated (Bio-Rad Gene Pulser) in a serum-free medium with 10  $\mu$ g of the following plasmids: pcDNA3-HA- $\Delta$ Np73 $\alpha$ , pcDNA3- $\Delta$ Np73 $\beta$ , and pcDNA3-HA-TAp73 $\epsilon$ . Twenty four h post-electroporation selection was applied (0.5 mg/ml G418), and individual clones were screened by Western blot assay. UT-7 cells were electroporated with 5  $\mu$ g of the indicated plasmids in a serum-free medium.

**Drugs and Erythroid Differentiation Analysis**—To examine the extent of erythroid differentiation, cells were treated with either vehicle control, or with 1  $\mu$ M AraC<sup>6</sup> (Calbiochem), 40  $\mu$ M hemin (Sigma), or 3 units/ml of human erythropoietin (EPO) (Sigma) in complete media. Hemoglobin-producing cells were scored by benzidine staining as described before (24). In each experiment at least 200 cells were counted in triplicate.

**Western Blot Analysis**—For protein analysis, cells were harvested after treatment with the indicated drug, processed as described before, resolved by SDS-PAGE, and detected by antibodies as indicated (25). The primary antibodies used were as follows: anti-p73 N-terminal (BL906 Abcam), anti-p73 C-terminal Ab-4 (NeoMarkers), anti-hemagglutinin (12CA5, Roche Applied Science), polyclonal anti-hemagglutinin (Y11, Santa Cruz Biotechnology), anti-p21 (C19, Santa Cruz Biotechnology), and anti-ERK2 (C14, Santa Cruz Biotechnology).

<sup>6</sup> The abbreviations used are: AraC, cytosine arabinoside; RT, reverse transcription; EPO, erythropoietin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ChIP, chromatin immunoprecipitation; oligo, oligonucleotide; siRNA, small interfering RNA; RE, responsive element; ERK, extracellular signal-regulated kinase.

**RNA Isolation, Semi-quantitative and Real Time RT-PCR Analysis**—Total RNA was extracted with TriReagent<sup>TM</sup> (Ambion) following the manufacturer's protocols. cDNA was prepared using SuperScript<sup>TM</sup> II First-Strand Synthesis System (Invitrogen) according to the manufacturer's instructions. Primer sequences used for PCR are described in [supplemental Table 1](#). The cycling program for p73 was set for 35 cycles at 95 °C for 5 min, 95 °C for 1 min, 60 °C for 1 min, 72 °C for 2 min, 72 °C for 10 min; for  $\Delta$ Np73: 39 cycles at 95 °C for 5 min, 95 °C for 1 min, 58 °C for 1 min, 72 °C for 2 min, 72 °C for 10 min; for GATA-1,  $\epsilon$ -globin, glycophorin A, transferrin receptor II, and p21<sup>CIP1</sup>: 24 cycles at 95 °C for 5 min, 95 °C for 1 min, 56 °C for 1 min, 72 °C for 1.5 min, 72 °C for 10 min; and for *GAPDH*: 30 cycles at 95 °C for 5 min, 95 °C for 1 min, 60 °C for 1 min, 72 °C for 2 min, and 72 °C for 10 min. The expression of erythroid markers mRNA in mouse fetal livers was detected by real time quantitative RT-PCR in a StepOnePlus<sup>TM</sup> real time PCR system (Applied Biosystems) using an iQ<sup>TM</sup> SYBR<sup>®</sup> Green SuperMix (Bio-Rad).

PCR was carried out at 50 °C for 2 min and 95 °C for 4 min, followed by 40 cycles of 95 °C for 1.5 min, 60 °C for 30 s, 72 °C for 30 s, and one cycle at 72 °C for 5 min. Primers sequences used for real time quantitative RT-PCR are described in [supplemental Table 2](#). The expression level of erythroid markers mRNA were expressed as  $2^{-CtGAPDH - Ct\text{erythroid markers}}$ , *Ct* indicates the cycle threshold. Each assay was performed at least in duplicate.

**Hematopoietic Indices**—Two-week-old mice were bled by cardiac puncture, and hematopoietic indices were determined by counting in a hemocytometer using different solutions as follows: Hayem's solution (Sigma) for red blood cell count, Turk's solution (Sigma) for white cell count, and procaine solution (Sigma) for platelet count according to the manufacturer's instructions. Each experiment was counted in triplicate. The final values are the average of the values for all mice from a given genotype. Hematocrit was determined with the Drabkin reagent following the manufacturer's protocols (Sigma).

**Flow Cytometry of Specific Erythroid Subpopulation**—Percentage of erythroid precursors in each erythroid development stage was measured as described elsewhere (26). Briefly, to analyze the most related erythroid precursors obtained from bone marrow and spleen,  $1 \times 10^6$  cells were stained with biotinylated murine anti-CD71 (Pharminogen) and TER-119-PE (Pharminogen) antibodies, washed, and incubated with streptavidin-tricolor (Caltag). A minimum number of  $3 \times 10^5$  viable cells was acquired using an EPICS XL flow cytometer (Coulter Electronics).

**Chromatin Immunoprecipitation (ChIP)**—For each ChIP assay ( $3 \times 10^7$  cells, or the fetal livers, were fixed in 1% formaldehyde, lysed, and sonicated as described in the Upstate protocol. ChIP was done using Dynabeads-protein G (Invitrogen) coupled to the following antibodies: anti-p73 N-terminal mixture (BL906 Abcam, anti-p73 N-terminal (Imgenex) and Ab-5 (NeoMarkers)), anti- $\Delta$ Np73 IMG-313A (Imgenex) and polyclonal anti-p53 (FL-393, Santa Cruz Biotechnology). Dynabeads were incubated with lysates, and chromatin was eluted and purified as described before (27). Real time PCR of immunoprecipitated DNA was performed in an iQ5 apparatus (Bio-

Rad) at 60 °C as the annealing temperature. Primers encompassing the p53-binding sites of the human p21 promoter were 5'-AGTTTGCAACCATGCACTTG and 5'-CTGATGCATGTGTGCTTGTG (amplicon, 180 bp).

An *in silico* prediction of p53-responsive elements (p53REs) within the human *GATA1* locus was performed with the p53FamTaG data base. Primers encompassing the p53-binding sites of the human *GATA1* promoter were 5'-GAAGAAATGGGGTGAGTCCA and 5'-GTGCTGAGTGGTTCCTACCC (amplicon, 199 bp).

**Luciferase Assay**—Cells were electroporated with reporter plasmid *GATA1-Luc* (2  $\mu$ g), 1  $\mu$ g of pRLNull (*Renilla* luciferase), and 5  $\mu$ g of the indicated expression vectors as follows: pcDNA-3, pcDNA3-TAp73 $\alpha$ , pcDNA3-TAp73 $\alpha$ 292, pcDNA3-HA- $\Delta$ Np73 $\alpha$ , pcDNA- $\Delta$ Np73 $\beta$ , or pcDNA3-HA-TAp73 $\epsilon$ . Cellular extracts were prepared as described before (22). Measurements were taken in a Berthold's luminometer and normalized by the values of the *Renilla* luciferase of the same sample.

**RNA Interference Analysis**—The knockdown of p73 was performed using two anti-p73 siRNA oligos described previously by Dr. Meredith Irwin (28). To ablate  $\Delta$ N-specific p73 isoforms, we used siRNA oligos described previously by Dr. A. Constanzo (29). All oligos used were synthesized by Dharmacon. Cells were electroporated with 100 nM siRNA oligos at 260 V and 1.05 millifarads (Bio-Rad Gene Pulser) in a serum-free medium and incubated for 48 h. Cells were treated with the indicated drug and incubated for 72 h; samples were collected at the indicated time and processed accordingly.

**Preparation of Labeled cDNA and Hybridization of Microarrays**—Total RNA from K562-V and K562-HA- $\Delta$ Np73 $\alpha$  cells was isolated with a RNeasy mini kit (Qiagen) following the manufacturer's protocol. Biotinylated cDNAs were hybridized with human genome U133 Plus 2.0 array (Affymetrix) in the Genomic Facility of Centro de Investigaciones del Cancer (Salamanca, Spain) (30). Data analysis and a hierarchical cluster tree were generated using dChip software. Analysis of each cell line and/or condition was based on RNAs prepared from two independent experiments.

## RESULTS


**p73 Isoforms Are Differentially Regulated during Erythroid Differentiation in K562**—To investigate the regulation and function of p73 variants (TA or  $\Delta$ N) during hematopoiesis, we analyzed the p73 expression pattern in chemically induced differentiation in the p53-deficient K562 cells. These cells differentiated into the erythroid lineage upon treatment with cytosine arabinoside (AraC), or natural regulators of erythropoiesis like hemin and EPO (31, 32). We examined the expression pattern of the different p73 variants in K562 cells under either proliferating conditions (not treated) or after treatment with AraC, hemin, or EPO. Semi-quantitative RT-PCR using specific sets of primers that discriminate between the different C-terminal isoforms showed induction of p73 $\alpha$  and - $\beta$  mRNA upon treatment (Fig. 1, A–C, upper panels). This induction peaks at day 3, coinciding with the onset of differentiation (32). To determine whether these p73 $\alpha$  and - $\beta$  transcripts represented TA and/or  $\Delta$ Np73 variants, we performed RT-PCR analysis with  $\Delta$ N-specific primers (Fig. 1, A–C, lower panels) and West-

ern blot analysis with an N-terminal (TA-specific) or a C-terminal (pan-p73) antibody (Fig. 1, D and E, respectively). We detected up-regulation of TAp73 $\alpha$  protein with all the treatments analyzed (Fig. 1, D and E). On the other hand,  $\Delta$ Np73 mRNA was up-regulated by AraC and hemin treatments (Fig. 1, A and B, lower panels), and consistently, we detected an up-regulation of  $\Delta$ Np73 $\alpha$  protein and to a minor extent  $\Delta$ Np73 $\beta$  upon AraC treatment (Fig. 1E). However, we did not detect  $\Delta$ Np73 up-regulation upon EPO treatment (Fig. 1C, lower panels).

To examine whether p73 regulation during erythroid differentiation was also present in another human model of erythroid differentiation, we used UT-7 cells, a human megakaryoblastic leukemia cell line with erythroid potential only upon treatment with EPO (33). Consistent with a prevalent function in erythroid differentiation, TAp73 $\alpha$  was up-regulated after EPO treatment in UT-7 cells (Fig. 1F).

**Constitutive Expression of  $\Delta$ Np73 Induces Erythroid Differentiation**—The differential modulation of p73 isoforms (TAp73 $\alpha$  and  $\Delta$ Np73 $\alpha$  and - $\beta$ ) during erythroid differentiation suggests a possible function for them in the process. We addressed this question via the generation of stable K562 cell lines expressing TAp73 $\alpha$ ,  $\Delta$ Np73 $\alpha$ , or  $\Delta$ Np73 $\beta$ . We also transfected K562 cells with TAp73 $\epsilon$  expression plasmid as a control, because of its lack of growth suppression function despite the presence of the TA domain (6). Although several clones expressing  $\Delta$ Np73 $\alpha$ ,  $\Delta$ Np73 $\beta$ , and TAp73 $\epsilon$  were obtained, we repeatedly failed to get TAp73 $\alpha$ -expressing clones. Therefore, we hypothesize that constitutive TAp73 $\alpha$  expression was not compatible with long term culture in these cells. Two recombinant clones from each genotype were selected for further analysis (termed K562- $\Delta$ Np73 $\alpha$ -C48 and -C29, K562- $\Delta$ Np73 $\beta$ -C8 and -C2, and K562-TAp73 $\epsilon$ -C2 and -C130). These transfectant clones showed different levels of the transgene-encoded proteins (Fig. 2A). We next asked if the expression of these p73 isoforms affected K562 differentiation. To this end, K562 cells, as well as K562- $\Delta$ Np73 $\alpha$ , - $\Delta$ Np73 $\beta$ , and -TAp73 $\epsilon$  cells, were treated with AraC, hemin, or EPO. Differentiation was analyzed by a benzidine staining (Fig. 2, B–D) and expression analysis of erythroid-specific markers ( $\epsilon$ -globin, glycophorin A, and *GATA1*) (Fig. 2E). Surprisingly,  $\Delta$ Np73 $\alpha$  and - $\beta$  clones, but not TAp73 $\epsilon$ , presented a significantly higher fraction of erythroid-differentiated cells than K562 under identical cell culture conditions in the absence of drugs (Fig. 2B). It is of note that the level of differentiation observed in each clone was proportional to the amount of  $\Delta$ Np73 protein expressed, and even a moderate amount of  $\Delta$ Np73 expression, like in clone C29 (Fig. 2A), resulted in a significant enhancement of erythroid differentiation (Fig. 2B). Furthermore,  $\Delta$ Np73 clones presented a greater percentage of differentiated cells upon drug treatment than did the controls (Fig. 2, C and D). In sharp contrast with the effects of  $\Delta$ Np73 $\alpha$  and - $\beta$ , TAp73 $\epsilon$  expression neither induced differentiation nor affected the fraction of hemoglobinized cells in response to AraC (Fig. 2, B and C) indicating that the observed phenotype was specific, and not because of a mere overexpression of a p73 isoform. Consistent with the enhanced hemoglobin production of the  $\Delta$ Np73 clones (Fig. 2B), real time RT-PCR analysis revealed that these clones expressed a higher level of the erythroid markers in non-

## Role of TP73 in Erythroid Differentiation



**FIGURE 1. p73 isoforms are regulated during erythroid differentiation induced by AraC, hemin, and EPO in K562.** A–C, expression of ΔN and TA p73 isoforms analyzed in K562 cells by semi-quantitative RT-PCR using specific primers for the different C-terminal p73 isoforms (*upper panels*) or the ΔN isoforms (*lower panels*). D–F, expression of TA and ΔNp73 isoforms in K562 (D and E) or UT-7 cells (F) was analyzed by Western blot analysis using anti-N-terminal, TA-specific antibody (D and F) or C-terminal pan-specific antibody (E). In all cases, samples were collected either under nontreated conditions (NT) or at different time points (days D1–D5) after the indicated treatment. Total ERK2 or GAPDH expression was assessed as loading control. The figures are representative of at least three independent experiments.

treated conditions as well as with AraC than controls (Fig. 2E), thus confirming the pro-erythroid differentiation conditions induced by ΔNp73.

To further substantiate that the ΔNp73 clones were differentiating according to a normal erythroid program, a molecular characterization of ΔNp73-mediated differentiation was performed. For that purpose, a genome-wide analysis of gene expression through microarray hybridization was carried out in K562-ΔNp73α-C48, K562-ΔNp73β-C8, and K562-V cells. After filtering and statistical analysis, we found that ΔNp73α regulated 2805 genes with  $\geq 3.45$ -fold changes and with a signal difference of  $\geq 100$ , between both experimental conditions and  $p < 0.001$  (data not shown). As expected for an erythroid phenotype, a set of erythroid-specific genes (33 genes) was significantly up-regulated in the ΔNp73α cells (Table 1) (31, 34–70). These included erythroid markers (hemoglobins, glycophorins, transferrin receptor, Rh-related antigens, or ALAS-2) as well as several erythroid-determining genes such as *GATA1* and *NFE2* (31, 34–70). Moreover, genes reported to be repressed during erythroid differentiation, like cyclin D1 and *MEIS* or *FOSB*, were down-regulated in ΔNp73α cells (Table 1) (68–70).

Microarray analysis of the ΔNp73β clones revealed a similar profile to those of ΔNp73α (data not shown).

*ΔNp73 Induces Accumulation of Transcriptionally Active TAp73, Which Is Necessary for the Erythroid Phenotype*—We observed that some of the genes up-regulated in the K562-ΔNp73 transcriptome of the cell, like *p21<sup>CIP1</sup>*, *BTG2*, *GDF15*, or *REELIN*, were p53 and/or TAp73 target genes (Fig. 3A and data not shown). Because K562 cells lack p53, we hypothesized that the up-regulation of some of these genes could be p73-dependent. To address this question, we first investigated the status of endogenous TAp73 in these cells. In K562 cells we detected a low level of TAp73α protein, which rapidly increased upon AraC treatment (Fig. 1E and Fig. 3A). However, elevated levels of the TAp73α protein level were observed in nontreated ΔNp73 clones, comparable with those detected in treated K562 cells (Fig. 3A). This accumulation of TAp73α protein in ΔNp73-expressing cells is in agreement with previously reported stabilization of TAp73α by ΔNp73 (71). Furthermore, in all the clones analyzed TAp73 level was proportional to the amount of transgenic ΔNp73 expressed (data not shown), suggesting that ΔNp73 was responsible of the TAp73 accumula-




TABLE 1

Data analysis of microarray, constitutive  $\Delta$ Np73 expression induces regulation of erythroid differentiation-related genes

	Transcription factors	ID	-Fold change	Ref.
<b>Transcription factors</b>				
<i>ALAS2</i>	Aminolevulinate, $\delta$ -, synthase 2 (sideroblastic/hypochromic anemia)	212	12.93	1, 2
<i>GATA1</i>	GATA-binding protein 1 (globin transcription factor 1)	2623	2.68	3, 4
<i>KLF1</i>	Kruppel-like factor 1 (erythroid)	10,661	2.45	5, 6
<i>NFE2</i>	Nuclear factor (erythroid-derived 2), 45 kDa	4778	2.09	7, 8
<i>STAT5B</i>	Signal transducer and activator of transcription 5B	6777	1.89	9, 10
<i>TAL1</i>	T-cell acute lymphocytic leukemia 1	6886	2.41	11, 12
<i>HEY1</i>	Hairy/enhancer-of-split related with YRPW motif 1	23,462	-5.87	13
<b>Membrane and cytoplasmic proteins</b>				
<i>TFRC</i>	Transferrin receptor (p90, CD71)	7037	8.58	14
<i>BCL2L1</i>	BCL2-like 1	598	3.38	15, 16
<i>CD44</i>	CD44 molecule (Indian blood group)	960	2	17, 18
<i>EPB41</i>	Erythrocyte membrane protein band 4.1 (elliptocytosis 1, RH-linked)	2035	13.83	19, 20
<i>EPB49</i>	Erythrocyte membrane protein band 4.9 (dematin)	2039	2.69	21, 22
<i>GYP A</i>	Glycophorin A (MNS blood group)	2993	10.58	23
<i>GYP B</i>	Glycophorin B (MNS blood group)	2994	9.06	22, 24
<i>GYP C</i>	Glycophorin C (Gerbich blood group)	2995	7.05	23
<i>GYP E</i>	Glycophorin E	2996	5.64	25
<i>HBA1</i>	Hemoglobin, $\alpha$ 1	3039	3.19	26
<i>HBA2</i>	Hemoglobin, $\alpha$ 2	3040	2.24	26
<i>HBB</i>	Hemoglobin, $\beta$	3043	2.71	26
<i>HBBP1</i>	Hemoglobin, $\beta$ pseudogene 1	3044	3.55	26
<i>HBD</i>	Hemoglobin, $\delta$	3045	4.24	26
<i>HBZ</i>	Hemoglobin, $\zeta$	3050	6.37	26
<i>HMBS</i>	Hydroxymethylbilane synthase	3145	4.33	7, 27
<i>HMGN</i>	Hemogen	55,363	5.07	28
<i>MCL1</i>	Myeloid cell leukemia sequence 1 (BCL2-related)	4170	50.02	29, 30
<i>RHCE</i>	Rh blood group, CcEe antigens	6006	5.49	31
<i>RHD</i>	Rh blood group, D antigen	6007	5.52	31
<i>RHAG</i>	Rh-associated glycoprotein	6005	4.88	32
<i>PTA1</i>	Spectrin, $\alpha$ , erythrocytic 1 (elliptocytosis 2)	6708	10.77	33
<i>SPTB</i>	Spectrin, $\beta$ , erythrocytic (includes spherocytosis, clinical type 1)	6710	2.38	34
<i>CCND1</i>	Cyclin D1	595	-7.94	35, 36
<i>FOSB</i>	FBJ murine osteosarcoma viral oncogene homolog B	2354	-83.21	37
<i>MEIS1</i>	Meis1, myeloid ecotropic viral integration site 1 homolog (mouse)	4211	-2.18	38

tion. Moreover, a strong TAp73 induction, with a concomitant increase in hemoglobin-producing cells, was detected in K562 cells transiently transfected with an inducible  $\Delta$ Np73 expression plasmid (Fig. 3, B and C), ruling out the possibility of an artifact due to the selection of a clone resistant to p73 growth inhibition. Consistently, constitutive expression of  $\Delta$ Np73 $\alpha$  and - $\beta$  in UT-7 cells also resulted in an increase of endogenous TAp73 $\alpha$  protein (supplemental Fig. 1A).


The former results suggest that  $\Delta$ Np73 results in elevated TAp73 protein, which in turn could regulate p73 target genes. To substantiate this hypothesis, we next investigated if TAp73 was transcriptionally regulating one of its classical targets, p21<sup>Cip1</sup>, in the  $\Delta$ Np73-expressing cells (Fig. 3A). ChIP assays with TAp73-specific antibodies demonstrated that TAp73 was recruited to the p53-binding site of the p21<sup>Cip1</sup> promoter upon treatment (Fig. 4A), suggesting a role for TAp73 in drug-induced p21<sup>Cip1</sup> expression in K562.

Analysis of the growth kinetics of the  $\Delta$ Np73 clones demonstrated that these cells presented a slower growth rate than K562 controls even though cell cycle analysis did not reveal a significant accumulation of cells in either G<sub>1</sub> or G<sub>2</sub>/M phase of

the cycle (supplemental Fig. 2, A and B). Congruently, they expressed elevated levels of p21<sup>Cip1</sup> under not treated conditions (Fig. 3A). Moreover, endogenous TAp73 was bound to the p21<sup>Cip1</sup> promoter, despite the presence of high levels of  $\Delta$ Np73 in these cells (Fig. 4A). To rule out the possibility that the results were due to the lack of specificity of the TAp73 antibody, we analyzed the binding of these proteins to the p53-response element of the pro-apoptotic NOXA promoter. No significant PCR product of this response element, or the p21<sup>Cip1</sup>, was obtained when we immunoprecipitated with the TAp73 antibody untreated K562 extracts (Fig. 4B). Furthermore, lack of significant PCR product with the anti-p53 antibody further demonstrated the specificity of the assay (Fig. 4, A and B).

$\Delta$ Np73 inhibitory function is exerted either by forming heterotetramers with TAp73 or by competing for binding to the same DNA target sequence (72, 73). However, despite the elevated levels of the  $\Delta$ Np73 protein, we did not detect  $\Delta$ Np73 binding to the p21<sup>Cip1</sup> promoter in the  $\Delta$ Np73 clones (Fig. 4A). Nevertheless, under the same experimental conditions we were able to detect both TAp73 and  $\Delta$ Np73 binding to the NOXA promoter, indicating the presence of heterodimers in this pro-

FIGURE 2. **Constitutive expression of  $\Delta$ Np73 induces erythroid differentiation and enhances K562 differentiation potential.** A, analysis of  $\Delta$ Np73 or TAp73e protein expression in stably transfected K562 cells. Western blot analysis of six of the obtained clones is as follows:  $\Delta$ Np73 $\alpha$ C29 and C48 (left panel),  $\Delta$ Np73 $\beta$  C2 and C8 (upper right panel), and TAp73e C2 and C130 (lower right panel). B–E, expression of  $\Delta$ Np73 results in spontaneous erythroid differentiation and enhances AraC, hemin, and EPO induction of differentiation in K562. B–D, percentage of benzidine-positive cells was assessed in the indicated clones under nontreated culture conditions (B and NT), after 5 days of AraC or hemin treatment (C), or after 4 days with EPO (D). In all cases a minimum of 200 cells was counted in triplicate. The data are mean values from at least three independent experiments. Error bars indicate S.E. (\*,  $p < 0.05$ ; \*\*,  $p < 0.005$ ). E, real time quantitative RT-PCR analysis of erythroid differentiation markers as follows:  $\epsilon$ -globin, glycophorin A, and GATA1 of K562 control cells or representative clones expressing  $\Delta$ Np73 $\alpha$  (K562- $\Delta$ Np73 $\alpha$ C48 and K562- $\Delta$ Np73C8  $\beta$ ). The experiments were performed at least three times, and similar results were obtained.



**FIGURE 3.  $\Delta$ Np73 induces accumulation of transcriptionally active TAp73.** *A*, Western blot analysis of endogenous TAp73 $\alpha$  and p21<sup>Cip1</sup> in nontreated conditions (NT) or following treatment with AraC (D1–D3) in K562 cells or in K562- $\Delta$ Np73 $\alpha$  and - $\beta$  clones without treatment. *B* and *C*, Western blot analysis of endogenous TAp73 $\alpha$  and induced HA- $\Delta$ Np73 (*B*) or percentage of benzidine positive cells (*C*) in samples of K562 cells transiently transfected with an inducible HA- $\Delta$ Np73 expression plasmid or empty vector and collected at different time points upon activation with zinc.


motor and suggesting that TA and  $\Delta$ N isoforms were not binding to all the promoters in the same way (Fig. 4, *A* and *B*).

Therefore, we sought to investigate whether the binding of TA and  $\Delta$ Np73 to a growth arrest promoter, like p21<sup>Cip1</sup>, would be different depending on the cellular context. For that purpose, we transfected  $\Delta$ Np73 $\alpha$  or - $\beta$  into UT-7 or the human colon carcinoma cell line HCT116 p53<sup>-/-</sup>, both containing endogenous TAp73, under the same experimental conditions. ChIP assays showed that  $\Delta$ Np73 $\alpha$  or - $\beta$  transfection in UT-7 cells resulted in preferential binding of endogenous TAp73 over  $\Delta$ Np73 (TA >  $\Delta$ N) to the p21<sup>Cip1</sup> promoter with a concurrent p21<sup>Cip1</sup> expression (Fig. 4, *C* and *D*). However, in HCT116p53<sup>-/-</sup> cells there was a  $\Delta$ Np73 preferential binding over TAp73 to the promoter ( $\Delta$ N  $\geq$  TA), with no induction of p21<sup>Cip1</sup> expression (Fig. 4, *C* and *D*). These results support the hypothesis in which the outcome of p73 isoforms interaction will depend on the cellular context.


Nevertheless, TAp73 recruitment to the p21<sup>Cip1</sup> promoter might not necessarily indicate transcriptional activity. Thus, we next asked whether TAp73 was required for p21<sup>Cip1</sup> expression in  $\Delta$ Np73 cells. p73 knockdown was performed using two different siRNAs that inhibit expression of either TAp73 isoforms specifically (siRNA-p73-3) or all the p73 variants (siRNA-p73-4) (28). These siRNAs have been previously published and demonstrated to be efficacious siRNA constructs that are

restricted to p73 and have no homology to p63 (74). Western blots were quantified by densitometric analysis and the values normalized to those of the total ERK values. We observed that the pan-p73 siRNA-p73-4 in K562- $\Delta$ Np73 $\beta$  cells repressed 33% of TAp73 $\alpha$  and 61% of  $\Delta$ Np73 $\beta$  expression (Fig. 5*A*). This inhibition resulted in an 80% decrease in p21<sup>Cip1</sup> expression (Fig. 5*A*), denoting the requirement of functional p73 for p21<sup>Cip1</sup> expression. However, in conditions in which TA-specific siRNA-p73-3 resulted in no significant reduction of  $\Delta$ Np73 $\beta$  transgene expression (only -2.4%), but knocked down 28% of TAp73, a comparable repression of p21<sup>Cip1</sup> (-75%) was obtained (Fig. 5*A*). Thus, a slight modulation of TAp73 expression, in the presence of sustained expression of  $\Delta$ Np73 $\beta$ , was sufficient to abate p21<sup>Cip1</sup> levels, in a similar manner to those obtained when all p73 forms were affected by the siRNA-p73-4. Consistently, a decrease in p21<sup>Cip1</sup> level was observed by RT-PCR analysis with both sets of siRNA (Fig. 5*C*). Similar results were obtained when the experiments were performed in the  $\Delta$ Np73 $\alpha$  clone (Fig. 5, *A* and *C*). Furthermore, p73 knockdown alleviated the slower rate of proliferation of the  $\Delta$ Np73-expressing cells (supplemental Fig. 2*C*). These data demonstrated that the endogenous TAp73 was required for p21<sup>Cip1</sup> expression in  $\Delta$ Np73 clones. Therefore, in K562 cells,  $\Delta$ Np73 expression results in the accumulation of transcriptionally active TAp73.

## Role of TP73 in Erythroid Differentiation







**FIGURE 5. TAp73 $\alpha$  functional inhibition results in suppression of p21<sup>Cip1</sup> expression and attenuation of erythroid differentiation in the K562- $\Delta$ Np73 cells.** *A–D*, K562- $\Delta$ Np73 $\alpha$  and - $\beta$  cells were transfected with annealing buffer only (*mock*) or siRNA against either all p73 isoforms (*siRNA p73-4*), TAp73 specific (*siRNA p73-3* marked with a *star*),  $\Delta$ Np73-specific (*siRNA- $\Delta$ Np73*), or scrambled control (*siRNA-scr*). After 72 h, samples were collected, and endogenous TAp73, transgenic  $\Delta$ Np73, and p21<sup>Cip1</sup> were analyzed by Western blot (*A* and *D*), benzidine assays (*B*), and RT-PCR of p21<sup>Cip1</sup> and erythroid markers (*C*). For each  $\Delta$ Np73 clone, the percentage of benzidine-positive cells obtained in the mock conditions was considered 100%, and the rest of the values were normalized to this one. The data are mean values from three independent experiments. Error bars indicate S.E. (\*\*,  $p < 0.005$ ). The asterisk in *A* refers to a nonspecific band.


We next asked whether TAp73 played a role in the erythroid phenotype of these clones. To that extent, we analyzed the effect of p73 knockdown in the erythroid differentiation of  $\Delta$ Np73 clones. Partial inhibition of p73 with the pan-p73 siRNA resulted in a 42–44% decrease in the fraction of hemoglobinized cells (Fig. 5*B*, siRNA-p73-4) with a concomitant attenuation of expression of the erythroid differentiation markers (Fig. 5*C*), pointing to a relevant role of p73 in this process. Furthermore, 28–33% knockdown of TAp73 with the TA-specific siRNA-p73-3 resulted in a significant 34–38% reduction of differentiated cells in  $\Delta$ Np73 $\alpha$  and - $\beta$  clones, respectively (Fig. 5, *B* and *C*), despite the remaining elevated levels (98%) of  $\Delta$ Np73 (Fig. 5*A*). This result demonstrates that  $\Delta$ Np73 is not sufficient to induce erythroid differentiation, and it requires the expression of TAp73 for this func-

tion. It is important to note that in our working conditions we do not knock down TAp73 completely, and hence, we still detect p21<sup>Cip1</sup> as well as erythroid differentiation levels above those of nontreated K562 cells.

It is noteworthy that in  $\Delta$ Np73 clones the pan-p73 siRNA-p73-4 only attained a partial TAp73 repression (33–44%), although in identical experimental conditions it silenced close to 90% of the AraC-induced TAp73 expression in parental cells (see Fig. 7, *A* and *D*, and Fig. 9*A*). This could be a reflection of the enhanced stability of TAp73 protein in the presence of  $\Delta$ Np73. Furthermore, abatement of  $\Delta$ Np73 expression in the  $\Delta$ Np73 clones, using a previously validated  $\Delta$ N-specific siRNA oligonucleotide with no sequence homology to TAp73 (29), resulted in a strong decrease of the TAp73 $\alpha$  protein (Fig. 5*D*). Under the same experimental condition, these oligos did not

**FIGURE 4. p73 is recruited to the p53 response element (RE) of the p21<sup>Cip1</sup> (A) or the NOXA promoter (B and C) in a context-dependent manner.** Chromatin immunoprecipitation assays (ChIP) of K562 untreated or treated for 3 days with AraC or K562- $\Delta$ Np73  $\alpha$  and  $\beta$  cells without treatment were performed using no antibody (H<sub>2</sub>O), anti-p53, anti- $\Delta$ Np73, or anti-TAp73 antibodies. Real time RT-PCR using primers to amplify the region encompassing p53RE of the human p21<sup>Cip1</sup> or NOXA promoters was performed, and the data were normalized to input chromatin samples in each case. *C* and *D*, UT-7 or HCT116p53<sup>-/-</sup> cells were transfected with  $\Delta$ Np73 expression plasmid, and 24 h later, ChIP assays were performed as before to analyze p73 recruitment to the p53RE of the p21<sup>Cip1</sup> (*C*), and p21<sup>Cip1</sup> expression levels were quantified by real time RT-PCR (*D*). The data are mean values from at least three independent experiments. NT, not treated. Error bars indicate S.E. (\*,  $p < 0.05$ ; \*\*,  $p < 0.005$ ).

## Role of TP73 in Erythroid Differentiation



**FIGURE 6. TAp73 $\alpha$  induces GATA1 activity, binds to the GATA1 promoter, and induces erythroid differentiation.** *A*, transcriptional analysis was performed in K562 cells transiently transfected with the GATA1-*luciferase* reporter promoter together with the indicated expression vectors. Luciferase activity was normalized by the *Renilla* activity of the same lysate. The data represent the mean of at least three experiments. *B*, endogenous TAp73 is recruited to the p53RE of the GATA1 promoter. ChIP of K562 control cells, untreated or with AraC for 3 days, or  $\Delta$ Np73-K562 ( $\alpha$  and  $\beta$  clones) under nontreated conditions were performed using no antibody (H<sub>2</sub>O), anti-p53, anti- $\Delta$ Np73, or anti-TAp73 antibodies. Real time RT-PCR using specific primers to amplify p53-binding sites of the human GATA1 promoter was performed, and the data were normalized to input chromatin samples of each case. *C*, K562 cells were transiently transfected with the indicated p73 expression vectors, and the percentage of benzidine-positive cells was assessed at different time points under normal culture conditions. The data are mean values from at least three independent experiments. Error bars indicate S.E. (\*,  $p < 0.05$ ; \*\*,  $p < 0.005$ ).

affect TAp73 $\epsilon$  protein levels in the TAp73 $\epsilon$ -expressing clones, despite its sequence homology with TAp73 $\alpha$ , ruling out the possibility that the siRNAs were directly affecting TAp73 $\alpha$ . Neither affected the expression of the co-transfected green fluorescent protein vector under conditions in which  $\Delta$ Np73 $\beta$  expression was repressed, excluding the possibility that the  $\Delta$ N-specific siRNAs affected the viability of the transfected cells (supplemental Fig. 3), altogether suggesting that  $\Delta$ Np73 is responsible of the accumulation of TAp73 $\alpha$ .

Knockdown of  $\Delta$ Np73, and therefore TAp73, also resulted in a significant repression of erythroid differentiation comparable with that obtained by the pan-p73 siRNAs (Fig. 5, *B* and *D*). Therefore, in K562 cells  $\Delta$ Np73 expression brings about TAp73 protein accumulation, which is required for the erythroid differentiation.

**GATA1 Is a Direct Target of TAp73, Which Is Required for Erythroid Differentiation in K562 Cells**—Our previous results indicate that TAp73 has a pro-erythroid differentiation function in K562- $\Delta$ Np73 cells. Furthermore, GATA1, a transcription factor determinant in erythropoiesis, together with some of its known targets (*ALAS2*, *NFE2*, *EPOR*, hemoglobins, and *Bcl-XL*) (37, 75) was found to be up-regulated in K562- $\Delta$ Np73 cells (Fig. 2*E* and Table 1). Hence, we hypothesized the existence of a functional link between p73 and GATA1. We first examined whether constitutive expression of TAp73 could induce GATA1 activity. We used a GATA1-*luc* reporter gene containing three GATA1-binding sites (23). Transient transfection of TAp73 $\alpha$ , but not TAp73 $\epsilon$  or TAp73 $\alpha$ 292, a DNA-binding incompetent mutant, significantly activated the GATA1-*luc* reporter (Fig. 6*A*).

To determine whether *GATA1* was a direct transcriptional target of TAp73 $\alpha$ , we performed an *in silico* prediction of p53-responsive elements within the human *GATA1* locus using p53Family-TargetGenes data base (76). We identified a p53-response element within the human *GATA1* promoter at position  $-3.326$  kb (ACCCTTGTCTTAGCTCTTAGACATGCCTCGAGCCTGCCA). This sequence lies within a region considered a transcriptional control element located between  $-3.9$  and  $-2.6$  kb 5' to the erythroid first exon that is sufficient to recapitulate *GATA1* expression in the primitive and definitive erythroid lineages (77). ChIP assays with TAp73- and  $\Delta$ Np73-specific antibodies demonstrated that TAp73 but not  $\Delta$ Np73 was bound significantly to the *GATA1* promoter in K562 parental cells treated with AraC for 3 days (Fig. 6B). In  $\Delta$ Np73 clones TAp73, but not  $\Delta$ Np73, was recruited to this p53-binding site (Fig. 6B). Consistently, transient expression of TAp73 $\alpha$ , but not TAp73 $\alpha$ 292, induced erythroid differentiation in K562 cells (Fig. 6C).

The capacity of p73 to modulate *GATA1* led us to propose that p73 could play a direct role in promoting erythroid maturation rather than a mere regulation of growth suppression through p21<sup>Cip1</sup>. To substantiate this claim, we first asked whether p73 was necessary for chemically induced erythroid differentiation using two compounds that triggered differentiation by different mechanisms. Even though p21<sup>Cip1</sup> expression correlates with erythroid differentiation in many experimental models, it is not essential for all drug-induced differentiations (31). AraC inhibits cell proliferation inducing p21<sup>Cip1</sup> expression, whereas hemin selectively activates the embryonic and fetal globin synthesis without inducing p21<sup>Cip1</sup> or cell cycle arrest (31). p73 knockdown, with pan-p73 and TA-specific siRNA, in K562 cells treated with either AraC (Fig. 7, A–C) or hemin (Fig. 7, D–F) resulted in a significant reduction of hemoglobinized cells and a decrease in the expression of the erythroid markers. It is noteworthy that in both scenarios p73 functional inhibition decreases *GATA1* expression (Fig. 7, C and F). These results confirm that the role of *TP73* in erythroid differentiation is not dependent only on the induction of p21<sup>Cip1</sup> or cell cycle arrest but corresponds to a common pathway of drug-induced differentiation shared by these drugs. Moreover, electroporation of K562 cells with the  $\Delta$ Np73-si-RNA-specific oligos resulted in a comparable inhibition of AraC-induced erythroid differentiation (Fig. 8, A and B). Nevertheless, this inhibition was accompanied with a moderate (18%) reduction of AraC-induced TAp73 $\alpha$  (Fig. 8, C and D) despite the demonstrated specificity of these oligos. However, even in conditions in which p73 knockdown was very effective, we still detected a percentage of hemoglobinized cells above the nontreated control, suggesting the existence of p73-independent mechanisms of drug-induced erythroid differentiation.


**p73 $\alpha$  Function Is Required for EPO-induced Erythroid Differentiation in K562 and UT-7 Cell Lines and Plays a Role in Vivo in Erythropoiesis**—To address whether p73 function was necessary during physiological erythropoiesis, we first analyzed p73 requirement in EPO-induced erythroid differentiation in K562 cells (Fig. 9, A–C). As a second model, we studied p73 involvement in EPO-induced differentiation in UT-7 cells (Fig. 9, D–F). We have previously demonstrated that in these cells

TAp73 $\alpha$  accumulation, induced by ectopic expression of  $\Delta$ Np73 $\alpha$ , was accompanied by a moderate increase in benzidine-positive cells (from 5% in vector-transfected cells to 13–15% in  $\Delta$ Np73 $\alpha$ - and  $-\beta$  transfected, respectively) (supplemental Fig. 1, A and B).

A partial p73 knockdown with siRNA-p73 in EPO-treated K562 cells resulted in an attenuation of hemoglobinized cells and in a sharp decrease in expression of erythroid markers (Fig. 9, A–C). Next we tested the effects of p73 silencing in UT-7 cells. Similar results were obtained with electroporation of 150–200 nM siRNA-p73-4 (Fig. 9, D–F). In these cells electroporation with 100 nM oligos did not achieve a significant repression of TAp73 $\alpha$  expression (supplemental Fig. 4) and therefore did not significantly repress EPO-induced erythroid differentiation (Fig. 9E). Altogether these data indicate that TAp73 function is required, at least in part, for appropriate EPO-induced erythroid differentiation in human myeloid cells.

We next sought to investigate the possible role of p73 in physiological hematopoiesis *in vivo*. Because definitive hematopoiesis in the mouse embryo takes place in the fetal liver, we first analyzed whether p73 would bind to the p53RE within the *Gata1* promoter in fetal livers of E14.5 embryos. ChIP analysis revealed that TAp73 and p53, but not  $\Delta$ Np73, bind to this promoter *in vivo* (Fig. 10A), suggesting that *Gata1* is an *in vivo* transcriptional target of p73. As a control, we performed ChIP analysis with fetal livers from p73KO E14.5 littermates (4) and did not detect any TAp73 binding (Fig. 10A). Because erythroid differentiation is dose-dependent with respect to *GATA1* (37), we hypothesized that in the p73KO mice, lack of p73 could result in impaired *GATA1* expression and therefore deficient erythropoiesis. We analyzed *GATA1* expression in fetal livers of E14.5 p73KO embryos and control littermates. Real time quantitative RT-PCR analysis revealed significantly lower levels of *GATA1* in p73KO when compared with control littermates (Fig. 10B). Consistently, expression of *GATA1* target genes such as *ALAS-e*,  $\epsilon$ -globin, or regulators like *c-Kit*, were also significantly diminished (Fig. 10B). Accordingly, macroscopic analysis revealed that 60% of p73KO embryos presented a pallor phenotype suggesting an anemic state (supplemental Fig. 5). Peripheral blood analysis of p73KO young mice (2 weeks old) confirmed a mild degree of anemia with 25% reduction in the red blood cells and 38% less hematocrit value than the control littermates (Table 2). Older animals were not analyzed because the half-life of p73KO mice is between 15 and 20 days (4). To further analyze the effect of p73 ablation on physiological hematopoiesis, we utilized a flow cytometric assay, with surface markers TER119 $\backslash$ CD71 labeling, previously validated as an excellent method to quantify erythroid precursors and the maturation stage of differentiation in the hematopoietic tissue (78, 79). We observed a highly significant 2-fold accumulation (supplemental Fig. 5,  $p < 0.005$ ) on the pre-committed erythroid progenitor (TER119<sup>low</sup>/CD71<sup>med</sup>) population in the bone marrow of P15 p73KO mice compared with control littermates (Fig. 10C). This accumulation could represent a blockage in the erythroid differentiation process before the commitment to pro-erythroblast. However, once the cells are committed to the erythroid differentiation, we did not detect any differences in the number of differentiated erythrocytes between wild type

## Role of TP73 in Erythroid Differentiation



**FIGURE 7. p73 functional inhibition attenuates drug-induced erythroid differentiation in K562 cells.** A–F, p73 siRNA decreases the differentiation potential of AraC and hemin. siRNA was performed as before in K562 cells, and 48 h later the cells were treated with AraC (A–C) or hemin (D–F). Samples were collected 3 days after treatment to perform Western blot analysis (A and D), benzidine assays (B and E), and RT-PCR of erythroid-specific markers (C and F). The data are mean values from three independent experiments. Error bars indicate S.E. (\*,  $p < 0.05$ ; \*\*,  $p < 0.005$ ). NT, not treated.




FIGURE 8.  $\Delta$ Np73 functional inhibition attenuates AraC-induced erythroid differentiation in K562 cells. siRNA was performed as before in K562 cells, and 48 h later the cells were treated with AraC. Samples were collected 3 days after treatment to perform benzidine assays (A), RT-PCR of erythroid-specific markers (B), or Western blot analysis (C and D). D, TAp73 $\alpha$  protein expression from C was quantified by densitometry, normalized by the loading controls, and represented as relative value to the scrambled siRNA. The data are mean values from three independent experiments. Error bars indicate S.E. (\*,  $p < 0.05$ ; \*\*,  $p < 0.005$ ). NT, not treated.

and p73KO bone marrow cells (Fig. 10C and supplemental Fig. 5). Altogether, these data support the role of p73 in physiological erythropoiesis.


## DISCUSSION

There is ample evidence indicating that leukemia, as well as other myeloproliferative disorders, result from alterations in

the differentiation of hematopoietic cells (31). Therefore, investigation of the cellular and molecular processes involved in physiological, as well as abnormal, hematopoiesis could be very valuable in the understanding and treatment of these diseases.

Despite their sequence homology, the p53 family members possess both common as well as nonoverlapping functions (3). p73 maintains a specific role in cellular differentiation and

## Role of TP73 in Erythroid Differentiation






**FIGURE 9. p73 function is required for EPO-induced erythroid differentiation in K562 and UT-7 cells.** A–F, siRNA was performed as before in K562 or UT-7 cells, and 48 h later the cells were treated with EPO. Samples were collected 3 days after treatment for Western blot analysis (A and D), benzidine assays (B and E), and RT-PCR of erythroid-specific markers (C and F). The data are mean values from at least three independent experiments. Error bars indicate S.E. (\*,  $p < 0.05$ ; \*\*,  $p < 0.005$ ). NT, not treated.

development (22, 80, 81). The regulation of cellular differentiation has been described as a mechanism of tumor suppression (82). In this line, the role of p73 in leukemogenesis has been

associated with its ability to regulate differentiation (19, 20, 83). In this study we provide a comprehensive analysis of the regulation and function of p73 variants during erythroid differentiation

ation in K562 cells. Previous studies have shown that the K562 represents an important *in vitro* model for basic studies of hematopoietic differentiation (31). To investigate the regulation of p73 in hematopoietic cells, we examined the expression profile of p73 in the K562 cells under various culture conditions. We show that TAp73 $\alpha$  was up-regulated by all the erythroid differentiation treatments analyzed, although  $\Delta$ Np73 was up-regulated during AraC and hemin treatment. This regulation is also present in the EPO-induced differentiation of the human megakaryoblastic leukemia cell line UT-7. The modulation of specific p73 isoforms suggests a function for these isoforms in erythroid differentiation.

Although transient expression of TAp73 induced GATA1 activity and erythroid differentiation, we barely detected exogenous HA-TAp73 expression, or benzidine-positive cells, after 72 h post-transfection. This supports the hypothesis that constitutive expression of TAp73 $\alpha$  at high levels, in the absence of  $\Delta$ Np73 expression, is lethal in K562, making stable expression of TAp73 $\alpha$  incompatible with long term cell culture. However, constitutive expression of  $\Delta$ Np73 ( $\alpha$  and  $\beta$ ) results in enhanced erythroid differentiation in the two myeloid cell lines analyzed. Furthermore, in this work we have demonstrated that although  $\Delta$ Np73 is necessary for the accumulation of the transcriptionally active TAp73, which is required for erythroid differentiation, it is not sufficient for the erythroid phenotype in the K562- $\Delta$ Np73 clones. Moreover, we have shown that attenuation of  $\Delta$ Np73 expression hinders AraC-induced differentiation in K562 cells. This observation suggests that, in this context,  $\Delta$ Np73 expression works as a positive regulator of erythroid differentiation, and it is consistent with the recent observation that  $\Delta$ Np73 acts as a pro-differentiation factor in acute promyelocytic leukemia cells and might be necessary for myeloid differentiation (19).



## Role of TP73 in Erythroid Differentiation

**TABLE 2**

Hematopoietic indices: p73KO mice showed moderated anemia in comparison with littermates

Mouse type	Mouse number	Hemoglobin	Hematocrit	Red blood cell count	White blood cell count	Platelet count
		g/dl	%	$\times 10^6/\text{mm}^3$	$\times 10^3/\text{mm}^3$	$\times 10^4/\text{mm}^3$
Wild type	13	7.2 $\pm$ 0.67	32.92 $\pm$ 1.07	327.92 $\pm$ 20.86	2.63 $\pm$ 0.39	37.15 $\pm$ 3.25
p73KO	11	4.7 $\pm$ 0.59 <sup>a</sup>	27.86 $\pm$ 0.64 <sup>b</sup>	241.85 $\pm$ 15.41 <sup>b</sup>	1.95 $\pm$ 0.33 <sup>a</sup>	34.57 $\pm$ 2.87

<sup>a</sup>  $p < 0.05$ .

<sup>b</sup>  $p < 0.005$ .

This scenario would be in apparent contradiction with the trans-dominant function of  $\Delta\text{Np73}$ . This inhibitory function is exerted at the oligomerization level and/or by competing for binding to the DNA target sequences. Furthermore,  $\Delta\text{Np73}$  can act as a transcription factor by binding to the promoter of its targets genes (14, 15, 18). However, it has been recently proposed that  $\Delta\text{Np73}\alpha$  could not only act as an inhibitor of p53/TAp73 functions but could also cooperate with p53 in the activation of certain genes in a cellular context-dependent manner (14, 15, 18). We have shown that TAp73 is present as homotetramers in the promoters in which it is active, like p21<sup>CIP1</sup> or GATA1, because we do not detect  $\Delta\text{Np73}$  binding in the same experimental conditions in which we can detect binding to the NOXA promoter. However,  $\Delta\text{Np73}$  expression is required for the long term induction of erythroid differentiation by TAp73 in K562 cells. These results corroborate the need for  $\Delta\text{Np73}$  expression, along with TAp73 $\alpha$ , to produce a stable erythroid phenotype in these cells. It is possible that  $\Delta\text{Np73}$  is acting as a survival factor that protects the cells from the apoptosis resulting from the enhanced TAp73 expression occurring during the differentiation process, without hindering TAp73 pro-differentiation function. From this perspective the lack of induction of  $\Delta\text{Np73}$  by EPO could be explained as the absence of a selective pressure for an additional anti-apoptotic mechanism, because EPO, by itself, promotes erythroid cell survival by regulating Bcl-X<sub>L</sub> expression through the JAK2/STAT5 pathway (84).  $\Delta\text{Np73}$  could exert this anti-apoptotic function by directly inducing the expression of anti-apoptotic genes like HSP70 (49), and/or by suppressing TAp73 transactivation of pro-apoptotic genes through the formation of heterotetramers.

We propose that the outcome of p73 isoform interactions will depend on the cellular context. Accordingly, in multipotent myeloid cells like K562 or UT-7,  $\Delta\text{Np73}$  will selectively block pro-apoptotic TAp73 target promoters (like NOXA) while allowing preferential TAp73 binding to, and transactivation of, the cell cycle arrest and pro-differentiation promoters (like p21<sup>CIP1</sup> and GATA1), resulting in differentiation induction and survival of the differentiated cell. However, in a differentiation-incompetent epithelial cell line (HCT116 p53<sup>-/-</sup>),  $\Delta\text{Np73}$  will block binding of TAp73 to all the target genes inhibiting TAp73-induced growth arrest and apoptosis. In accordance

with this hypothesis, we have demonstrated that in K562 or UT-7 cells there is a preferential binding of TAp73 versus  $\Delta\text{Np73}$  to promoters like p21<sup>CIP1</sup> and GATA1. However, that is not the case in pro-apoptotic promoters like NOXA where a preferential  $\Delta\text{Np73}$  versus TAp73 binding is observed. Furthermore, while in UT-7 cells  $\Delta\text{Np73}$  transfection resulted in preferential endogenous TAp73 binding to the p21<sup>CIP1</sup> promoter with a concomitant p21<sup>CIP1</sup> expression, in HCT116p53<sup>-/-</sup> cells resulted in  $\Delta\text{Np73}$  preferential binding to the p21<sup>CIP1</sup> promoter with no p21<sup>CIP1</sup> expression. However, although our results support the hypothesis in which the outcome of p73 isoform interactions will depend on the cellular context, the molecular mechanism of this selective cooperation remains to be deciphered.

The hematopoietic system requires a continual replacement of cells through the life span of the organism. This is achieved through self-renewal of the hematopoietic stem cells and their sequential commitment to progenitor and precursor cells. The molecular mechanisms that determine these cell fate decisions are regulated by lineage-specific transcription factors (GATA1, KLF1, TAL1, SP1, PU.1, etc.) working in conjunction with general transcription factors (85). In our work, we have observed that in K562, a cell line with characteristics of multipotent progenitor cells, constitutive expression of  $\Delta\text{Np73}$  up-regulates some of these lineage-specific factors (GATA1, KLF1, and TAL1) probably through the up-regulation of TAp73 $\alpha$ . Moreover, we have demonstrated for the first time that GATA1 is a direct target of TAp73 $\alpha$  *in vitro* and *in vivo*. Furthermore, we have shown that reduction in p73 expression results in an impaired induction of GATA1 during drug-induced erythroid differentiation by EPO, hemin, and AraC in K562 and EPO-treated UT-7 cells.

GATA1 is a zinc finger transcription factor that plays a central role in erythroid development being a master regulator of terminal differentiation of erythroid precursors. Strikingly, analysis of p73KO embryos livers showed a significantly diminished expression in the fetal liver of *Gata1* and other erythroid related genes, including globins. We also detected a significant decrease in the expression of *c-Kit*, known to be required for the optimal production of red cells *in vivo* through the collaboration with erythropoietin receptor and GATA1 (86). The altered

**FIGURE 10. p73 plays a physiological role in developmental hematopoiesis.** A, endogenous TAp73 is recruited to the p53RE of the *Gata1* promoter *in vivo*. ChIP of E14.5 fetal livers extracts of wild type (WT) and p73KO (ko) embryos were performed using no antibody (H<sub>2</sub>O), anti-GATA1, anti-p53, anti- $\Delta\text{Np73}$ , or anti-TAp73 antibodies. Real time RT-PCR using specific primers to amplify p53-binding sites of the human *GATA1* promoter was performed, and the data were normalized to input chromatin samples of each case. B, real time quantitative RT-PCR analysis of GATA1 and erythroid-related genes such as *ALAS-e*,  $\epsilon$ -globin, and *c-Kit* in E14.5 p73KO livers compared with control littermates (WT). The data are mean values from at least three independent experiments from all the mice of each genotype (wild type,  $n = 7$ ; p73KO,  $n = 6$ ). Error bars indicate S.E. (\*,  $p < 0.05$ ; \*\*,  $p < 0.005$ ). C, representative example of the assessment of erythroid developmental stages in bone marrow of p73KO or wild type P15 mice. Cells at different stages were identified by double staining with anti-TER-119 and anti-CD71 antibodies. RI, TER119<sup>low</sup>/CD71<sup>med</sup>, pre-committed erythroid progenitor; RII, CD71<sup>high</sup>/TER-119<sup>low</sup>, proerythroblasts; RIII, CD71<sup>high</sup>/TER-119<sup>high</sup>, basophilic erythroblasts; RIV, CD71<sup>low-med</sup>/TER-119<sup>high</sup>, polychromatic and orthochromatic erythroblasts; RV, CD71<sup>-</sup>/TER-119<sup>high</sup> mature erythroid cells. The data are representative examples from all the mice of each genotype (wild type,  $n = 5$ ; p73KO,  $n = 5$ ).



levels of important regulators of erythroid differentiation *in vivo* in the p73KO embryos support the idea that TP73 fulfills a relevant function in this process. Moreover, peripheral blood analysis of p73KO 2-week-old mice confirmed moderated anemia in these animals, suggesting that p73 is required, at least in part, during erythropoiesis. In an attempt to state at which step of erythropoiesis p73 may play a role, we performed a flow cytometric assay that allows quantitative evaluation of erythroid differentiation in hematopoietic tissues (78, 79). We observed that lack of p73 resulted in an accumulation of the pre-committed erythroid progenitor population in the bone marrow of P15 p73KO mice. This accumulation could represent a blockage in the erythroid differentiation process before the commitment to pro-erythroblast. However, once the cells are committed to the erythroid differentiation, we do not detect any differences in the number of differentiated erythrocytes between wild type and p73KO bone marrow cells. An alternative explanation could be that the enhanced number of erythroid progenitors reflects a defect in the p73KO mice to increase their erythropoietic rate in response to stress (such as anemic state). Although further studies are needed to establish the requirement of TP73 in the development of hematopoietic precursors, our data point to a physiological role of the TP73 gene in erythropoiesis.

*Acknowledgments*—We thank all the people cited in the text for their generous gift of reagents. We are grateful to Dr. A. Fernández for helpful advice and discussion of the manuscript.

## REFERENCES

- Bourdon, J. C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., and Lane, D. P. (2005) *Genes Dev.* **19**, 2122–2137
- Melino, G., De Laurenzi, V., and Vousden, K. H. (2002) *Nat. Rev. Cancer* **2**, 605–615
- Murray-Zmijewski, F., Lane, D. P., and Bourdon, J. C. (2006) *Cell Death Differ.* **13**, 962–972
- Yang, A., Walker, N., Bronson, R., Kaghad, M., Oosterwegel, M., Bonnin, J., Vagner, C., Bonnet, H., Dikkes, P., Sharpe, A., McKeon, F., and Caput, D. (2000) *Nature* **404**, 99–103
- Ishimoto, O., Kawahara, C., Enjo, K., Obinata, M., Nukiwa, T., and Ikawa, S. (2002) *Cancer Res.* **62**, 636–641
- De Laurenzi, V., Costanzo, A., Barcaroli, D., Terrinoni, A., Falco, M., Annicchiarico-Petruzzelli, M., Levrero, M., and Melino, G. (1998) *J. Exp. Med.* **188**, 1763–1768
- Moll, U. M., and Slade, N. (2004) *Mol. Cancer Res.* **2**, 371–386
- Jost, C. A., Marin, M. C., and Kaelin, W. G., Jr. (1997) *Nature* **389**, 191–194
- Fang, L., Lee, S. W., and Aaronson, S. A. (1999) *J. Cell Biol.* **147**, 823–830
- Jung, M. S., Yun, J., Chae, H. D., Kim, J. M., Kim, S. C., Choi, T. S., and Shin, D. Y. (2001) *Oncogene* **20**, 5818–5825
- De Laurenzi, V., Rossi, A., Terrinoni, A., Barcaroli, D., Levrero, M., Costanzo, A., Knight, R. A., Guerrieri, P., and Melino, G. (2000) *Biochem. Biophys. Res. Commun.* **273**, 342–346
- Zaika, A. I., Slade, N., Erster, S. H., Sansome, C., Joseph, T. W., Pearl, M., Chalas, E., and Moll, U. M. (2002) *J. Exp. Med.* **196**, 765–780
- Petrenko, O., Zaika, A., and Moll, U. M. (2003) *Mol. Cell. Biol.* **23**, 5540–5555
- Tanaka, Y., Kameoka, M., Itaya, A., Ota, K., and Yoshihara, K. (2004) *Biochem. Biophys. Res. Commun.* **317**, 865–872
- Tanaka, Y., Ota, K., Kameoka, M., Itaya, A., and Yoshihara, K. (2006) *Exp. Cell Res.* **312**, 1254–1264
- Liu, G., Nozell, S., Xiao, H., and Chen, X. (2004) *Mol. Cell. Biol.* **24**, 487–501
- Kartasheva, N. N., Lenz-Bauer, C., Hartmann, O., Schäfer, H., Eilers, M., and Döbelstein, M. (2003) *Oncogene* **22**, 8246–8254
- Goldschneider, D., Million, K., Meiller, A., Haddada, H., Puisieux, A., Bénard, J., May, E., and Douc-Rasy, S. (2005) *J. Cell Sci.* **118**, 1245–1253
- Mainardi, S., Pelosi, A., Palescandolo, E., Riccioni, R., Fontemaggi, G., Diverio, D., Testa, U., Sacchi, A., Grignani, F., Lo-Coco, F., Levrero, M., Blandino, G., and Rizzo, M. G. (2007) *Cell Death Differ.* **14**, 1968–1971
- Tschan, M. P., Grob, T. J., Peters, U. R., Laurenzi, V. D., Huegli, B., Kreuzer, K. A., Schmidt, C. A., Melino, G., Fey, M. F., Tobler, A., and Cajot, J. F. (2000) *Biochem. Biophys. Res. Commun.* **277**, 62–65
- Peters, U. R., Tschan, M. P., Kreuzer, K. A., Baskaynak, G., Lass, U., Tobler, A., Fey, M. F., and Schmidt, C. A. (1999) *Cancer Res.* **59**, 4233–4236
- Fernandez-Garcia, B., Vaqué, J. P., Herreros-Villanueva, M., Marques-Garcia, F., Castrillo, F., Fernandez-Medarde, A., León, J., and Marín, M. C. (2007) *Cell Death Differ.* **14**, 254–265
- Takahashi, T., Suwabe, N., Dai, P., Yamamoto, M., Ishii, S., and Nakano, T. (2000) *Oncogene* **19**, 134–140
- Delgado, M. D., Lerga, A., Cañelles, M., Gómez-Casares, M. T., and León, J. (1995) *Oncogene* **10**, 1659–1665
- Marin, M. C., Jost, C. A., Irwin, M. S., DeCaprio, J. A., Caput, D., and Kaelin, W. G., Jr. (1998) *Mol. Cell. Biol.* **18**, 6316–6324
- Meza, N. W., Quintana-Bustamante, O., Puyet, A., Rio, P., Navarro, S., Diez, A., Bueren, J. A., Bautista, J. M., and Segovia, J. C. (2007) *Hum. Gene Ther.* **18**, 502–514
- Wu, S., Cetinkaya, C., Munoz-Alonso, M. J., von der Lehr, N., Bahram, F., Beuger, V., Eilers, M., Leon, J., and Larsson, L. G. (2003) *Oncogene* **22**, 351–360
- Irwin, M. S., Kondo, K., Marin, M. C., Cheng, L. S., Hahn, W. C., and Kaelin, W. G., Jr. (2003) *Cancer Cell* **3**, 403–410
- Papoutsaki, M., Lanza, M., Marinari, B., Nisticò, S., Moretti, F., Levrero, M., Chimenti, S., and Costanzo, A. (2004) *J. Invest. Dermatol.* **123**, 1162–1168
- Berwanger, B., Hartmann, O., Bergmann, E., Bernard, S., Nielsen, D., Krause, M., Kartal, A., Flynn, D., Wiedemeyer, R., Schwab, M., Schäfer, H., Christiansen, H., and Eilers, M. (2002) *Cancer Cell* **2**, 377–386
- Tsiftoglou, A. S., Pappas, I. S., and Vizirianakis, I. S. (2003) *Pharmacol. Ther.* **100**, 257–290
- Neri, L. M., Bortul, R., Tabellini, G., Borgatti, P., Baldini, G., Celeghini, C., Capitani, S., and Martelli, A. M. (2002) *Cell. Signal.* **14**, 21–29
- Jacobs-Helber, S. M., and Sawyer, S. T. (2004) *Blood* **104**, 696–703
- Watanabe, T., Mitchell, T., Sariban, E., Sabbath, K., Griffin, J., and Kufe, D. (1985) *Mol. Pharmacol.* **27**, 683–688
- Cox, T. C., Bawden, M. J., Martin, A., and May, B. K. (1991) *EMBO J.* **10**, 1891–1902
- Kawasaki, N., Morimoto, K., Tanimoto, T., and Hayakawa, T. (1996) *Arch. Biochem. Biophys.* **328**, 289–294
- Ferreira, R., Ohneda, K., Yamamoto, M., and Philipsen, S. (2005) *Mol. Cell. Biol.* **25**, 1215–1227
- Welch, J. J., Watts, J. A., Vakoc, C. R., Yao, Y., Wang, H., Hardison, R. C., Blobel, G. A., Chodosh, L. A., and Weiss, M. J. (2004) *Blood* **104**, 3136–3147
- Basu, P., Morris, P. E., Haar, J. L., Wani, M. A., Lingrel, J. B., Gaensler, K. M., and Lloyd, J. A. (2005) *Blood* **106**, 2566–2571
- Basu, P., Lung, T. K., Lemsaddek, W., Sargent, T. G., Williams, D. C., Jr., Basu, M., Redmond, L. C., Lingrel, J. B., Haar, J. L., and Lloyd, J. A. (2007) *Blood* **110**, 3417–3425
- Chan, J. Y., Han, X. L., and Kan, Y. W. (1993) *Proc. Natl. Acad. Sci. U.S.A.* **90**, 11366–11370
- Chénais, B. (1998) *Biochem. Biophys. Res. Commun.* **253**, 883–886
- Wang, J., Wang, C., Tsui, H. W., Las Heras, F., Cheng, E. Y., Iscove, N. N., Chiu, B., Inman, R. D., Pritzker, K. P., and Tsui, F. W. (2007) *Exp. Cell Res.* **313**, 4120–4129
- Snow, J. W., Abraham, N., Ma, M. C., Abbey, N. W., Herndier, B., and Goldsmith, M. A. (2002) *Blood* **99**, 95–101
- Brunet de la Grange, P., Armstrong, F., Duval, V., Rouyez, M. C., Goardon, N., Romeo, P. H., and Pflumio, F. (2006) *Blood* **108**, 2998–3004
- Schuh, A. H., Tipping, A. J., Clark, A. J., Hamlett, I., Guyot, B., Iborra, F. J.,

## Role of TP73 in Erythroid Differentiation

- Rodriguez, P., Strouboulis, J., Enver, T., Vyas, P., and Porcher, C. (2005) *Mol. Cell. Biol.* **25**, 10235–10250
47. Elagib, K. E., Xiao, M., Hussaini, I. M., Delehanty, L. L., Palmer, L. A., Racke, F. K., Birrer, M. J., Shanmugasundaram, G., McDevitt, M. A., and Goldfarb, A. N. (2004) *Mol. Cell. Biol.* **24**, 7779–7794
48. Shimizu, R., Trainor, C. D., Nishikawa, K., Kobayashi, M., Ohneda, K., and Yamamoto, M. (2007) *J. Biol. Chem.* **282**, 15862–15871
49. Garçon, L., Rivat, C., James, C., Lacout, C., Camara-Clayette, V., Ugo, V., Lecluse, Y., Bennaceur-Griscell, A., and Vainchenker, W. (2006) *Blood* **108**, 1551–1554
50. Hafid-Medheb, K., Augery-Bourget, Y., Minatchy, M. N., Hanania, N., and Robert-Lézénès, J. (2003) *Blood* **101**, 2575–2583
51. Ghaffari, S., Dougherty, G. J., Lansdorp, P. M., Eaves, A. C., and Eaves, C. J. (1995) *Blood* **86**, 2976–2985
52. Deguchi, T., Komada, Y., Sugiyama, K., Zhang, X. L., Azuma, E., Yamamoto, H., and Sakurai, M. (1999) *Exp. Hematol.* **27**, 542–552
53. Deguillien, M., Huang, S. C., Morinière, M., Dreumont, N., Benz, E. J., Jr., and Baklouti, F. (2001) *Blood* **98**, 3809–3816
54. Yang, G., Huang, S. C., Wu, J. Y., and Benz, E. J., Jr. (2008) *Blood* **111**, 392–401
55. Rana, A. P., Ruff, P., Maalouf, G. J., Speicher, D. W., and Chishti, A. H. (1993) *Proc. Natl. Acad. Sci. U.S.A.* **90**, 6651–6655
56. Wickenhauser, C., Pérez, F., Siebolts, U., Lorenzen, J., Varus, E., Frimpong, S., and Thiele, J. (2003) *Int. J. Oncol.* **23**, 437–443
57. Ferrari, B., and Pavia, A. A. (1986) *Int. J. Pept. Protein Res.* **28**, 456–461
58. Kudo, S., and Fukuda, M. (1994) *J. Biol. Chem.* **269**, 22969–22974
59. Morceau, F., Chénais, B., Gillet, R., Jardillier, J. C., Jeannesson, P., and Trentesaux, C. (1996) *Cell Growth Differ.* **7**, 1023–1029
60. Li, C. Y., Zhan, Y. Q., Xu, C. W., Xu, W. X., Wang, S. Y., Lv, J., Zhou, Y., Yue, P. B., Chen, B., and Yang, X. M. (2004) *Cell Death Differ.* **11**, 1299–1308
61. Jacobs-Helber, S. M., Abutin, R. M., Tian, C., Bondurant, M., Wickrema, A., and Sawyer, S. T. (2002) *J. Biol. Chem.* **277**, 4859–4866
62. Fukuchi, Y., Kizaki, M., Yamato, K., Kawamura, C., Umezawa, A., Hata, J., Nishihara, T., and Ikeda, Y. (2001) *Oncogene* **20**, 704–713
63. Wiener, E., Shiels, A., Wickramasinghe, S. N., and Avent, N. D. (1998) *Br. J. Haematol.* **103**, 259–267
64. Daniels, G., and Green, C. (2000) *Vox Sang.* **78**, Suppl. 2, 149–153
65. Boulanger, L., Sabatino, D. E., Wong, E. Y., Cline, A. P., Garrett, L. J., Garbarz, M., Dhermy, D., Bodine, D. M., and Gallagher, P. G. (2002) *J. Biol. Chem.* **277**, 41563–41570
66. Gallagher, P. G., Sabatino, D. E., Romana, M., Cline, A. P., Garrett, L. J., Bodine, D. M., and Forget, B. G. (1999) *J. Biol. Chem.* **274**, 6062–6073
67. Furukawa, Y. (2002) *Leuk. Lymphoma* **43**, 225–231
68. Kawano, T., Horiguchi-Yamada, J., Saito, S., Iwase, S., Furukawa, Y., Kano, Y., and Yamada, H. (2004) *Leuk. Res.* **28**, 623–629
69. Yen, J., Wisdom, R. M., Tratner, I., and Verma, I. M. (1991) *Proc. Natl. Acad. Sci. U.S.A.* **88**, 5077–5081
70. Ferretti, E., Villaescusa, J. C., Di Rosa, P., Fernandez-Diaz, L. C., Longobardi, E., Mazzieri, R., Miccio, A., Micali, N., Sella, L., Ferrari, G., and Blasi, F. (2006) *Mol. Cell. Biol.* **26**, 5650–5662
71. Slade, N., Zaika, A. I., Erster, S., and Moll, U. M. (2004) *Cell Death Differ.* **11**, 357–360
72. Grob, T. J., Novak, U., Maise, C., Barcaroli, D., Lüthi, A. U., Pirnia, F., Hügli, B., Graber, H. U., De Laurenzi, V., Fey, M. F., Melino, G., and Tobler, A. (2001) *Cell Death Differ.* **8**, 1213–1223
73. Stiewe, T., Theseling, C. C., and Pützer, B. M. (2002) *J. Biol. Chem.* **277**, 14177–14185
74. Lau, L. M., Nugent, J. K., Zhao, X., and Irwin, M. S. (2008) *Oncogene* **27**, 997–1003
75. Orkin, S. H. (1992) *Blood* **80**, 575–581
76. Sbisà, E., Catalano, D., Grillo, G., Licciulli, F., Turi, A., Liuni, S., Pesole, G., De Grassi, A., Caratozzolo, M. F., D'Erchia, A. M., Navarro, B., Tullo, A., Saccone, C., and Gisel, A. (2007) *BMC Bioinformatics* **8**, Suppl. 1, S20
77. Nishimura, S., Takahashi, S., Kuroha, T., Suwabe, N., Nagasawa, T., Trainor, C., and Yamamoto, M. (2000) *Mol. Cell. Biol.* **20**, 713–723
78. Socolovsky, M., Nam, H., Fleming, M. D., Haase, V. H., Brugnara, C., and Lodish, H. F. (2001) *Blood* **98**, 3261–3273
79. Zhang, J., Socolovsky, M., Gross, A. W., and Lodish, H. F. (2003) *Blood* **102**, 3938–3946
80. De Laurenzi, V., Raschellá, G., Barcaroli, D., Annicchiarico-Petruzzelli, M., Ranalli, M., Catani, M. V., Tanno, B., Costanzo, A., Levrero, M., and Melino, G. (2000) *J. Biol. Chem.* **275**, 15226–15231
81. Stiewe, T. (2007) *Nat. Rev. Cancer* **7**, 165–168
82. Sherr, C. J. (2004) *Cell* **116**, 235–246
83. Morena, A., Riccioni, S., Marchetti, A., Polcini, A. T., Mercurio, A. M., Blandino, G., Sacchi, A., and Falcioni, R. (2002) *Blood* **100**, 96–106
84. Silva, M., Benito, A., Sanz, C., Prosper, F., Ekhterae, D., Nuñez, G., and Fernandez-Luna, J. L. (1999) *J. Biol. Chem.* **274**, 22165–22169
85. Cantor, A. B., and Orkin, S. H. (2002) *Oncogene* **21**, 3368–3376
86. Wu, H., Liu, X., Jaenisch, R., and Lodish, H. F. (1995) *Cell* **83**, 59–67